Entitled "H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Secondary Analysis of the SISPCT Randomized Control Trial1" and published in Critical Care Medicine, the findings demonstrate Nu.Q® NETs H3.1 is a promising novel biomarker for early mortality and organ dysfunction in sepsis, with significantly higher levels found in septic shock than sepsis patients and a clear dose-response relationship with acute kidney injury severity. These findings indicate that Nu.Q® NETs H3.1 has potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis.

Critical Care Medicine also published an Editorial entitled "H3.1 Nucleosomes in Sepsis: A Biomarker, a Mechanism or Both?2" which concludes:

"Ultimately, the clinical value of H3.1 may lie less in its ability to predict outcomes than in its potential to identify a biologically distinct subgroup of patients with NET-mediated organ injury."

Dr Andrew Retter, Medical Consultant, Volition, said:

"We are honored that Nu.Q® NETs H3.1 featured in an editorial2 in Critical Care Medicine, a prominent journal for Critical Care doctors around the world and are excited to publish the findings of this large-scale independent clinical study.

"Nu.Q® NETs, Volition's nucleosome quantification technology, is a simple, low-cost, accessible test to detect diseases associated with NETosis. Although NETs play a critical role in our normal immune response, elevated levels of NETs can lead to tissue damage and, in severe cases, sepsis, organ failure, and death. These findings advance our understanding of nucleosome biology in critical illness and help inform future therapeutic strategies.

"Introducing Nu.Q® NETs into hospitals, as a treatable, trackable trait, could lead to new ways of treating sepsis, improve patient survival and the quality of life of survivors."

Professor Michael Bauer, Chair of the Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany and co-author of the paper said:

"Our study establishes H3.1 nucleosomes as a biomarker delineating organ dysfunction in sepsis, particularly for early mortality and the need for RRT. The clear stratification of risk and independence from conventional markers suggests clinical utility.

"Being able to predict a sepsis patient's clinical course early, by using Nu.Q® NETs in clinical practice, could significantly enhance sepsis management, enabling physicians more time to intervene and improve patient outcomes."

Mr. Remi Rabeuf, VP Corporate Alliances and Strategic Partnership, Volition added:

"We are currently advancing several active commercial discussions with significant players in the diagnostic space, including large markets such as sepsis; the findings from this peer-reviewed paper support this ongoing licensing process.

"This paper, together with previously published evidence1,3-5, demonstrates that Nu.Q® NETs should enable clinicians and researchers to anticipate disease, guide treatment decisions, and monitor patients over time, across both acute and chronic conditions.

"Nu.Q® NETs is a simple, low-cost, accessible test to detect diseases associated with NETosis such as sepsis. The market opportunity is significant with a Total Addressable Market of $2.8 billion6."